Monday, September 16, 2019

1 - Microglia and Depression


Overall, I thought this paper was an interesting and well-researched look at microglia through a different lens: that of a behavioral kind. While stress and depression have often been studied in a more holistic and circuit-level way, I think this paper provided insight into how small physical changes to the cells in our brain (ie. decrease in number and size of microglia) can result in behavioral modifications and induce depressive-like symptoms. I thought that the paper was well-written, with lots of background research to reinforce the results that the authors found, and reasonable explanations and conclusions drawn from their findings.
One thing that I noted while reading this paper was in the administration of the drugs imipramine and minocycline – in the materials and methods section, the authors note that these drugs were delivered via water, and that the doses calculated were only averages, as animals were housed together and doses were not administered individually. I don’t know whether or not that is common practice for drug administration in rodents, but I was slightly worried about the use of an ‘average’ dose for each rodent. If one were to consume significantly more than another, would this have an effect on the results? Later in the paper, the authors also discuss the lack of a statistically significant effect these drugs had on behavior despite the presence of a statistically significant effect on microglia status. They attribute this to timing, as they state that behavioral paradigms were completed hours before the animals were killed, allowing more time for the drugs to act on the brain tissue following behavioral testing. If the authors believe that a few hours would make a difference in their behavioral results, is variance in dosing not a concern? While both are smaller details, I just question why the authors would think that one would have an effect on their results while the other would not.
One thing that I particularly appreciated in this study was the use of the genetically modified rodent model, the IL-1raTG animals. Assuming I understood exactly what the model was used for (although I’m still not sure I completely do), I thought that this was an interesting addition, as opposed to using and exogenous antagonist to block the IL-1 signalling pathway. The use of an over-expressed endogenous antagonist seems to me more variable, but also has the potential to be compared to humans who may have variable amounts of sensitivity in this pathway due to their genetic backgrounds. Although these animals over-express the antagonist to a point of fault in the pathway, it is possible that some people naturally have more antagonist in their system and could then be more resistant to the deficits incurred while undergoing chronic stress. While I would like to read and understand more about this particular rodent model and its uses in different studies, I just thought that this was an interesting addition to an otherwise more drug-heavy study.

1 comment:

  1. Agreed about the dosing issue--not ideal, but it was the least invasive

    ReplyDelete

Note: Only a member of this blog may post a comment.